Rds in a premature infant is defined as respiratory distress requiring more than 30% oxygen delivered by positive pressure using either nasal cpap or an et tube with a chest radiograph that has. Exogenous surfactant is one of only a handful of neonatal therapies that has a strong evidence base, the product of countless basic and clinical studies over roughly 30 years between the first report of respiratory distress syndrome rds as surfactant deficiency and the food and drug administration fda approval of the first surfactant preparation. Exogenous surfactant therapy has become well established in newborn. Porcine versus bovine surfactant therapy for rds in preterm. It appears that surfactant replacement therapy for mas consistently improves gas exchange and shortterm outcomes, especially avoidance of air leaks and the need for ecmo. Surfactant replacement therapy is now an integral part of the care of neonates since several clinical trials of natural surfactant extracts and synthetic preparations have shown efficacy in the treatment of infants with hyaline membrane disease. Surfactant replacement therapy, either as a rescue treatment or a prophylactic natural surfactant therapy, reduces mortality evidence level 1a and several aspects of morbidity in babies with rds. Surfactant replacement therapy for preterm and term neonates. Bovine surfactants are known to be clinically equivalent but it is unclear if porcine or bovine. Who recommendation on surfactant replacement therapy for. In addition to respiratory distress syndrome, other neonatal respiratory disorders are. Update in surfactant therapy american academy of pediatrics. Synthetic surfactants versus natural animalderived surfactants for preterm neonates with clinical andor radiologically established respiratory distress syndrome rds.
Surfactant reduced both neonatal mortality and pulmonary air leaks by about 50%. Meconium aspiration syndrome mas, a common cause of respiratory failure in neonates, is associated with high mortality and morbidity. To study the effect of exogenous bovine surfactant on oxygen and ventilatory requirements in neonates with respiratory deterioration due to pulmonary hemorrhage. First generation protein free synthetic surfactants are not used nowadays. Term neonates usually have a surfactant storage pool of approximately 100 mgkg, whereas preterm neonates have an estimated pool only 45 mgkg at birth. Use of cpap and surfactant therapy in newborns with. The mean sd age at which surfactant was given was 5. Halliday in 1959 avery and mead demonstrated that surfactant deficiency was a key feature in the pathogenesis of respiratory distress syndrome rds. Respiratory distress syndrome rds is a major disease burden in the developing countries. Neonatal rds management before surfactant therapy duration.
This video shows administration of surfactant in nicu by dr ajay agadesurfactant is a novel and revolutionary therapy in management of respiratory distress syndrome in neonates. Late surfactant administration in very preterm neonates with. Synthetic lung surfactant drug information, professional. Current evidence supports early continuous positive airway pressure cpap use and early selective surfactant administration as the most efficacious interventions in the management of rds, both in developed and developing countries. Surfactant replacement therapy srt has a proven role in the treatment of neonatal respiratory distress syndrome and severe meconium aspiration syndrome in infants, and may have a role in the treatment of pediatric patients with ards. Surfactant replacement therapy srt in respiratory distress. In addition to respiratory distress syndrome, other neonatal respiratory disorders are characterized. Surfactant replacement therapy with a single postventilatory dose of a reconstituted bovine surfactant in preterm neonates with respiratory distress syndrome. Surfactant replacement therapy for preterm and term. Mechanical ventilator with flowvolume monitoring or manual neonatal. Surfactant therapy an overview sciencedirect topics. When a baby comes out of the womb and the lungs are not developed yet, they require administration of surfactant in order to process oxygen and survive. Infants who received surfactant following a clinically significant pulmonary hemorrhage during the time period july 1991. Infants receiving surfactantreplacement therapy required less ecmo, without a concomitant increase in complications.
Surfactant therapy and antibiotics in neonates with. Rds in a premature infant is defined as respiratory distress requiring more than 30% oxygen delivered by. Does nebulised surfactant benefit neonates with respiratory. Pdf surfactant replacement therapy for preterm and term. Bolus surfactant therapy by tracheal catheterization, another method of administering surfactant while avoiding ventilation, has been developed in german neonatal units. Exogenous surfactants are given at doses between 1020 times the normal pool sizes during surfactant replacement therapy which approximates the pool size in term infants.
Its introduction was also associated with a 6% reduction in infant mortality in the usa. Surfactants used in this manner are typically instilled directly into the trachea. Since the time when fujiwara first published in 1980, the use of a modified bovine surfactant on ten. Fortysix infants weighing 1499 g were randomized into two groups. Synthetic surfactant for respiratory distress syndrome in preterm infants synthetic surfactant is effective in reducing respiratory distress syndrome in preterm babies. Exogenous surfactant therapy increases the pool size rapidly and improves. Beyond respiratory distress syndrome steven m donn md and jennifer dalton md introduction meconium aspiration syndrome surfactant replacement surfactant lavage bronchopulmonary dysplasia summary surfactant replacement therapy is a lifesaving treatment for preterm infants with respiratory. Recommendations for neonatal surfactant therapy ncbi. In addition to respiratory distress syndrome rds, surfactant deficiency is observed in many other clinical situations in term and preterm infants, raising several questions regarding the use of surfactant therapy. Effect of surfactant on morbidity, mortality, and resource. Sep 01, 2009 surfactant replacement therapy is a lifesaving treatment for preterm infants with respiratory distress syndrome, a disorder characterized by surfactant deficiency. Surfactant replacement in neonates by brian walsh for openpediatrics duration. B protein components four surfactant proteins, called spa, spb, spc, and spd, have been identified. Pdf respiratory failure secondary to surfactant deficiency is a major cause of morbidity and mortality in preterm infants.
These morbidities include deficits in oxygenation, the incidence of pulmonary air leaks pneumothorax and pulmonary interstitial emphysema and. Pulmonary surfactant is a substance that prevents the air sacs of the lungs from collapsing by reducing surface tension. Surfactant therapy is one of the few treatments that have dramatically changed clinical practice in neonatology. Which types of surfactant are effective animalderived or synthetic. Although newer delivery mechanisms and strategies are being studied, the classic surfactant administration paradigm consists of endotracheal intubation. Ozek, prophylactic protein free synthetic surfactant for preventing morbidity.
Surfactant replacement therapy for neonates with respiratory. Neonatology intratracheally administered bronchoalveolar fluid derived from calves98% lipids, comprised of 90% phospholipid, especially dipalmitoylphosphatidylcholine and 2% apoproteins, which markedly improves gas exchange in premature infants. Proceedings of the exosurf neonatal treatment ind investigators meeting. Fujiwara t, konishi m, chida s, okuyama k, ogawa y, takecuchi y, et al. Father interacts with his 4 day old child on an incubator at a neonatal intensive care. Porcine vs bovine surfactant therapy for preterm neonates. Goat lung surfactant for treatment of respiratory distress. Guidelines for surfactant administration surfactant. Surfactant replacement therapy srt forms the cornerstone of management of moderate to severe respiratory distress syndrome rds among preterm neonates and it is associated with reduced. Surfactant replacement therapy for rds early rescue therapy should be practiced. An overview of pulmonary surfactant in the neonate.
Synthetic surfactant for respiratory distress syndrome in. Surfactant is composed of lipids, mainly phospholipids, and. According to established guidelines 64, mothers at risk of delivering babies with less. Evolution of surfactant therapy for respiratory distress. Surfactant replacement therapysrt, newborn, survival, risk factors, mortality accepted february 10 2012 introduction surfactant was the first drug developed exclusively for neonates 1. Surfactant replacement therapy definition of surfactant. Currently, exogenous surfactant therapy in adults with ards has failed to demonstrate any beneficial effect on outcome of either mortality or ventilatorfree days. Surfactant replacement therapy may be considered in. Respiratory distress syndrome rds due to surfactant deficiency is the most common cause of respiratory failure in preterm infants. Recommendations for neonatal surfactant therapy canadian. Some new synthetic surfactants containing protein analogues, including chf5633, have recently been studied. Currently, exogenous surfactant therapy in adults with ards has failed to demonstrate any beneficial effect on outcome of either mortality or ventilator free days.
Recommendations for neonatal surfactant therapy 2017. Surfactant replacement therapy srt for preterm neonates with clinical. Surfactant creates a continuously reforming surface layer. Furthermore, prophylactic surfactant administration has not been found to be superior to early selective surfactant administration if ncpap fails 3.
Apr 12, 2014 respiratory distress syndrome rds is a major disease burden in the developing countries. Bovine surfactants are known to be clinically equivalent but it is unclear if porcine or bovine surfactants at their licensed dose should be preferred to treat respiratory distress syndrome in preterm neonates. Surfactant was the first drug developed solely for treatment of neonates. Mist failure was defined as need for early mechanical ventilation surfactant in preterm infants introduction pulmonary surfactant is a complex mixture of phospholipids and proteins that serves to reduce alveolar surface tension. Obstetrics, gynecology and reproductive medicine guidelines. The gdg noted that proteinfree synthetic surfactants increase the risk. Both animal derived surfactant extracts and protein free synthetic surfactant extracts are effective in the treatment and prevention of respiratory distress syndrome. It is formed by type ii pneumocytes from about 20 weeks of gestation. Many clinical trials have demonstrated that surfactant replacement therapy is a. Surfactant therapy for acute respiratory failure in children. They showed that low surfactant protein values increased after surfactant administration, with an improvement in the clinical status of the infants, but the effects waned after 1 day. The surfactant lining alveolar surface is a prerequisite for gas exchange in order to fulfill the energy needs of the living organism. Surfactant replacement therapy for preterm and term neonates with.
Repletion with exogenous surfactant decreases mortality and thoracic air leaks and is a standard practice in the developed world. Surfactant replacement was established as an effective and safe therapy for immaturityrelated surfactant deficiency by the early 1990s. Surfactant treatment has been shown by careful randomised trials to reduce the mortality and morbidity of very premature babies. Exogenous surfactant is used to treat acute respiratory failure in children, although the benefits and harms in this setting are not clear. Sinkin, md, mph surfactant replacement therapy srt has a proven role in the treatment of neonatal respiratory distress syndrome and severe meconium aspiration syndrome in infants, and may have a role in the treatment of pediatric patients with ards. Minisymposium neonates surfactant therapy in the newborn c. Two basic strategies for surfactant replacement have emerged. Withdraw the mac catheter from the et tube as it severely reduces or occludes the et tube lumen and restricts ventilation which can lead to adverse events desaturation, bradycardia, and chest rigidity. Surfactant replacement therapy should be considered in. Brian walsh discusses the use of surfactant replacement therapy in the treatment of preterm and term neonates suffering from respiratory distress syndrome rds. In comparison with intubation, use of ncpap is associated with reduced need of surfactant administration, intubation and bronchopulmonary dysplasia in extremely preterm neonates 1, 2. Etiology of surfactant inactivation or dysfunction.
Surfactant replacement therapy srt, newborn, survival, risk factors, mortality accepted february 10 2012 introduction surfactant was the first drug developed exclusively for neonates 1. Surfactantreplacement therapy is a lifesaving treatment for preterm infants with respiratory distress syndrome, a disorder characterized by surfactant deficiency. It appears that surfactantreplacement therapy for mas consistently improves gas exchange and shortterm outcomes, especially avoidance of air leaks and the need for ecmo. The surfactantlining alveolar surface is a prerequisite for gas exchange in order to fulfill the energy needs of the living organism. Comparative trials demonstrate greater early improvement in the requirement for ventilator support, fewer pneumothoraces, and fewer deaths associated with animal derived. Who recommendation on the type of surfactant for surfactant. Porcine vs bovine surfactant therapy for preterm neonates with rds. Surfactant therapy is the medical administration of exogenous surfactant. The technique involves placement of a fine intratracheal catheter while babies keep spontaneously breathing on ncpap. Mist failure was defined as need for early mechanical ventilation in.
Pdf surfactant replacement therapy beyond respiratory. Surfactant replacement therapy beyond respiratory distress syndrome in neonates article pdf available in indian pediatrics 533. Sep 26, 2016 infants receiving surfactant replacement therapy required less ecmo, without a concomitant increase in complications. Surfactant therapy in neonates with respiratory deterioration. First dose needs to be given as soon as diagnosis of rds is made. Objective to evaluate incidence of minimally invasive surfactant therapy mist failure, identify risk factors and assess the impact of mist failure on neonatal outcome. Surfactant replacement in neonates by brian walsh for openpediatrics. In neonates with rds, surfactant therapy has proven to be efficacious, and in pediatric patients with ards, exogenous surfactant has reduced morbidity and mortality. Aarc clinical practice guideline surfactant replacement. Surfactant replacement therapy in neonatal respiratory. Beyond respiratory distress syndrome steven m donn md and jennifer dalton md introduction meconium aspiration syndrome surfactant replacement surfactant lavage bronchopulmonary dysplasia summary surfactantreplacement therapy is a lifesaving treatment for preterm infants with respiratory. Costeffectiveness of a synthetic surfactant therapy for neonatal respiratory distress syndrome. Animal derived surfactant compared to proteinfree synthetic.
897 1523 998 335 71 726 515 693 1305 1460 863 766 543 738 890 1488 760 987 643 688 1211 1222 295 964 82 838 1094 673 507 1243 887 641 1221 605 607 232 1110 1184 1128 1434 848 22 422 916 872 787